Back to Search
Start Over
Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
- Source :
- Journal of Intensive Care, Journal of Intensive Care, Vol 9, Iss 1, Pp 1-3 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
- Subjects :
- REMAP-CAP (Randomized
Population health
Critical Care and Intensive Care Medicine
Embedded
03 medical and health sciences
0302 clinical medicine
Political science
Health care
Pandemic
Global network
Letter to the Editor
Scope (project management)
RC86-88.9
business.industry
COVID-19
Emerging infectious disease
Medical emergencies. Critical care. Intensive care. First aid
030208 emergency & critical care medicine
Public relations
Clinical trial
030228 respiratory system
Randomized controlled trial
Scale (social sciences)
Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia)
business
Subjects
Details
- ISSN :
- 20520492
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Journal of Intensive Care
- Accession number :
- edsair.doi.dedup.....c7d3cdb3fa6cc61a15f46a799a091c3e